Kiadis Pharma announces closing of two private placements totalling
€17 million
THIS PRESS RELEASE AND THE INFORMATION
CONTAINED HEREIN IS RESTRICTED AND NOT FOR PUBLIC RELEASE,
PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR
INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN,
NEW ZEALAND, THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION
IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE
UNLAWFUL. PLEASE SEE THE IMPORTANT NOTICES AT THE END OF THIS PRESS
RELEASE.
THIS PRESS RELEASE CONTAINS INSIDE
INFORMATION FOR IMMEDIATE RELEASE.
Kiadis Pharma announces closing
of two private placements totalling €17
million
Amsterdam, The Netherlands, April 30,
2020 – Kiadis Pharma N.V. ( “Kiadis”, “Kiadis Pharma” or the
“Company”) (Euronext Amsterdam and Brussels: KDS), a
clinical-stage biopharmaceutical company, today announces that it
has closed private placements totalling EUR 17 million with two
healthcare focused investors. Kiadis plans to use the proceeds from
these transactions to continue to fund the development of the its
K-NK-cell therapy programs.
Arthur Lahr, CEO of Kiadis commented, “We are
very pleased to have completed these transactions, which together
will fund our business through near-term milestones with our K-NK
programs that we believe will create value for all
stakeholders.”
In April, Kiadis raised EUR 17 million in gross
proceeds through two private placements with healthcare-focused
investors, both of which closed today. Pursuant to the first EUR 12
million private placement, 7,490,637 new shares were issued at a
subscription price of EUR 1.60 per share, and 3,745,318 5-year
warrants with an exercise price of EUR 2.22 were granted. Of the
new shares, 5,800,000 have been admitted to listing and trading on
Euronext Amsterdam and Euronext Brussels as per today. In the
context of this private placement, the Company has agreed to a
lock-up undertaking not to issue further new shares for a period of
60 calendar days after the settlement date. In the event that the
volume weighted average share price has exceeded EUR 2.00 on any
trading day during the lock up period, the lock-up restriction
shall lapse on the later of the 45th day after the Closing Date and
the trading date that the VWAP has exceeded EUR 2.00.
Pursuant to the second EUR 5 million private
placement, 2,986,858 new shares were issued at a subscription price
of EUR 1.67 per share, and 1,493,429 5-year warrants with an
exercise price of EUR 2.32 were granted.
The remaining 1,690,637 new shares related to
the first private placement and the 2,986,858 new shares related to
the second private placement shall be admitted to listing and
trading on Euronext Amsterdam and Euronext Brussels as soon as
possible on the basis of a prospectus that the Company shall
prepare, get approved by the Netherlands Authority for the
Financial Markets (Stichting Autoriteit Financiële Markten) and
make generally available in accordance with the Prospectus
Regulation (EU) 2017/1129 and which shall be notified to the
Belgian Financial Services and Markets Authority (Autorité des
services et marchés financiers) for passporting in accordance the
Prospectus Regulation.
About Kiadis Pharma’s K-NK-Cell
Therapies Kiadis Pharma’s K-NK platform is designed to
deliver potent NK cells to help each patient, without the need for
genetic engineering. Kiadis Pharma’s programs consist of
off-the-shelf and haploidentical donor NK-cell therapy products for
the treatment of liquid and solid tumors as adjunctive and
stand-alone therapies.
The Company’s PM21 particle technology enables
improved ex vivo expansion and activation of cytotoxic NK cells
supporting multiple high-dose infusions. Kiadis Pharma’s
proprietary off-the-shelf NK-cell platform is based on NK cells
from unique universal donors and can make NK-cell therapy product
rapidly and economically available for a broad patient population
across a potentially wide range of indications.
Kiadis Pharma is developing K-NK002, which is
administered as an adjunctive immunotherapeutic on top of HSCT, and
K-NK003 for the treatment of relapse/refractory acute myeloid
leukemia. In addition, Kiadis Pharma has pre-clinical programs
evaluating NK-cell therapy for the treatment of solid tumors.
About Kiadis PharmaFounded in
1997, Kiadis Pharma is building a fully integrated
biopharmaceutical company committed to developing innovative
therapies for patients with life-threatening diseases. With
headquarters in Amsterdam, the Netherlands, and offices and
activities across the United States, Kiadis Pharma is reimagining
medicine by leveraging the natural strengths of humanity and our
collective immune system to source the best cells for life. The
Company’s shares are listed on the Euronext Amsterdam and Brussels
under the ticker KDS. Learn more at www.kiadis.com. Kiadis Pharma
is listed on the regulated market of Euronext Amsterdam and
Euronext Brussels since July 2, 2015, under the symbol KDS. Learn
more at kiadis.com.
For more information, please
contact:
Kiadis Pharma:
Maryann Cimino, Sr. Manager, Corporate Affairs Tel: +1 (617)
710-7305 m.cimino@kiadis.com |
Optimum Strategic
Communications: Mary Clark, Supriya Mathur, Hollie Vile
Tel: +44 203 950 9144 David Brilleslijper (Amsterdam) Tel: +31 610
942 514 kiadis@optimumcomms.com |
This press release is released by the Company
and contains inside information for the purposes of Article 7 of
the Market Abuse Regulation (EU) 596/2014 ("MAR"),
encompassing information relating to the private placements, and is
disclosed in accordance with the Company's obligations under
Article 17 of MAR.
For the purposes of MAR and Article 2 of
Commission Implementing Regulation (EU) 2016/1055, this press
release is being made on behalf of the Company by Arthur Lahr,
Chief Executive Officer.
Forward Looking
StatementsCertain statements, beliefs and opinions in this
press release are forward-looking, which reflect Kiadis Pharma’s
or, as appropriate, Kiadis Pharma’s officers’ current expectations
and projections about future events. By their nature,
forward-looking statements involve a number of known and unknown
risks, uncertainties and assumptions that could cause actual
results, performance, achievements or events to differ materially
from those expressed, anticipated or implied by the forward-looking
statements. These risks, uncertainties and assumptions could
adversely affect the outcome and financial effects of the plans and
events described herein. A multitude of factors including, but not
limited to, changes in demand, regulation, competition and
technology, can cause actual events, performance, achievements or
results to differ significantly from any anticipated or implied
development. Forward-looking statements contained in this press
release regarding past trends or activities should not be taken as
a representation that such trends or activities will continue in
the future. As a result, Kiadis Pharma expressly disclaims any
obligation or undertaking to release any update or revisions to any
forward-looking statements in this press release as a result of any
change in expectations or projections, or any change in events,
conditions, assumptions or circumstances on which these
forward-looking statements are based. Neither Kiadis Pharma nor its
advisers or representatives nor any of its subsidiary undertakings
or any such person’s officers or employees guarantees that the
assumptions underlying such forward-looking statements are free
from errors nor does either accept any responsibility for the
future accuracy of the forward-looking statements contained in this
press release or the actual occurrence of the anticipated or
implied developments. You should not place undue reliance on
forward-looking statements, which speak only as of the date of this
press release.
General
This press release is for information purposes
only and shall not constitute an offer to buy, sell, issue, or
subscribe for, or the solicitation of an offer to buy, sell, issue,
or subscribe for any securities, nor shall there be any offer,
solicitation or sale of securities in any jurisdiction in which
such offer, solicitation or sale would be unauthorised or unlawful
prior to registration or qualification under the securities laws of
any such jurisdiction. Any failure to comply with these
restrictions may constitute a violation of the securities law of
any such jurisdiction.
The new shares and warrants issued, or to be issued, in
connection with the private placements have not been and will not
be registered under the U.S. Securities Act 1933, as amended (the
"U.S. Securities Act") or with any securities
regulatory authority of any state or other jurisdiction of the
United States and may not be offered, sold, delivered or
transferred, directly or indirectly, in or into the United States
except pursuant to an exemption from, or in a transaction not
subject to, the registration requirements of the U.S. Securities
Act and in compliance with any applicable securities laws of any
state or other jurisdiction of the United States. This press
release does not constitute an offer of securities in the United
States, securities may not be offered or sold in the United States
absent registration or an exemption from registration under the
U.S. Securities Act. The Company does not intend to register any
portion of the private placements in the United States or to
conduct a public offering of securities in the United States.
This press release has been issued by and is the
sole responsibility of the Company. No representation or
warranty, express or implied, is or will be made as to, or in
relation to, and no responsibility or liability is or will be
accepted by Oppenheimer and & Co., Inc.
("Oppenheimer") (apart from the responsibilities
or liabilities that may be imposed by the regulatory regime
established thereunder) or by any of its affiliates or agents as
to, or in relation to, the accuracy or completeness of this press
release or any other written or oral information made available to
or publicly available to any interested party or its advisers, and
any liability therefor is expressly disclaimed.
Oppenheimer is acting as the sole placement
agent for the Company and for no-one else in connection with the
private placements, and Oppenheimer will not be responsible to
anyone other than the Company for providing the protections
afforded to its customers or for providing advice to any other
person in relation to the private placements or any other matter
referred to herein.
The distribution of this press release and the
offering of the new shares and warrants in certain jurisdictions
may be restricted by law. No action has been taken by the Company,
Oppenheimer or any of their respective directors, officers,
partners, agents, employees, affiliates and advisors that would
permit an offering of such shares or possession or distribution of
this press release or any other offering or publicity material
relating to such shares in any jurisdiction where action for that
purpose is required. Persons into whose possession this press
release comes are required to inform themselves about, and to
observe such restrictions.
The press release does not constitute a
recommendation concerning any investor's options with respect to
the private placements. The new shares and warrants to which this
press release relates may be illiquid and / or subject to
restrictions on their resale. Recipient of this press release
should conduct their own investigation, evaluation and analysis of
the business, data and property described in the press release. The
pricing and value of securities can go down as well as up. Past
performance is not a guide to future performance. The contents of
this press release are not to be construed as financial, legal,
business or tax advice. If you do not understand the contents of
this press release you should consult an authorised financial
adviser, legal adviser, business adviser or tax adviser for
financial, legal, business or tax advice.